Evidence map›Paper›PMID 36318700›Full record

ArticleAnalytical chemistry2022

Nanoplasmonic Avidity-Based Detection and Quantification of IgG Aggregates.

Thuy Tran, Erik Martinsson, Sergio Vargas, Ingemar Lundström, Carl-Fredrik Mandenius, Daniel Aili

Abstract read
In one paragraph

Article in Analytical chemistry, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Thuy TranLaboratory of Molecular Materials, Division of Biophysics and Bioengineering, Department of Physics, Chemistry and Biology, Linköping University, Linköping 581 83, Sweden.ORCID 0000-0002-6542-1338
Erik MartinssonArgusEye AB, Spannmålsgatan 55, Linköping 583 36, Sweden.
Sergio VargasWolfram MathCore AB, Teknikringen 1E, Linköping 583 30, Sweden.
Ingemar LundströmSensor and Actuator Systems, Department of Physics, Chemistry and Biology, Linköping University, Linköping 581 83, Sweden.
Carl-Fredrik MandeniusBiotechnology, Division of Biophysics and Bioengineering, Department of Physics, Chemistry and Biology, Linköping University, Linköping 581 83, Sweden.
Daniel AiliLaboratory of Molecular Materials, Division of Biophysics and Bioengineering, Department of Physics, Chemistry and Biology, Linköping University, Linköping 581 83, Sweden.ORCID 0000-0002-7001-9415

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Production of therapeutic monoclonal antibodies (mAbs) is a complex process that requires extensive analytical and bioanalytical characterization to ensure high and consistent product quality. Aggregation of mAbs is common and very problematic and can result in products with altered pharmacodynamics and pharmacokinetics and potentially increased immunogenicity. Rapid detection of aggregates, however, remains very challenging using existing analytical techniques. Here, we show a real-time and label-free fiber optical nanoplasmonic biosensor system for specific detection and quantification of immunoglobulin G (IgG) aggregates exploiting Protein A-mediated avidity effects. Compared to monomers, IgG aggregates were found to have substantially higher apparent affinity when binding to Protein A-functionalized sensor chips in a specific pH range (pH 3.8-4.0). Under these conditions, aggregates and monomers showed significantly different binding and dissociation kinetics. Reliable and rapid aggregate quantification was demonstrated with a limit of detection (LOD) and limit of quantification (LOQ) of about 9 and 30 μg/mL, respectively. Using neural network-based curve fitting, it was further possible to simultaneously quantify monomers and aggregates for aggregate concentrations lower than 30 μg/mL. Our work demonstrates a unique avidity-based biosensor approach for fast aggregate analysis that can be used for rapid at-line quality control, including lot/batch release testing. This technology can also likely be further optimized for real-time in-line monitoring of product titers and quality, facilitating process intensification and automation.

Indexed as

Antineoplastic Agents, ImmunologicalBiosensing TechniquesAntibodies, MonoclonalImmunoglobulin GLimit of DetectionProtein AggregatesAntibodies, MonoclonalAntineoplastic Agents, ImmunologicalImmunoglobulin GProtein Aggregates

Identifiers

PMID36318700
PMCPMC9670026

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.